PET Imaging for Abdominal Aortic Aneurysm (AAA)
This study is looking at a new way to image abdominal aortic aneurysms (AAAs), which are bulges in the main artery of your belly. Researchers are testing a special imaging agent called Cu-64-RYM2 with PET/CT scans. They want to see how well Cu-64-RYM2 shows up in AAA segments. The study will involve healthy volunteers and patients with AAA who are having surgery. The main goal is to see if the Cu-64-RYM2 signal can be measured in AAA segments, with results expected in two years. The study is planning to enroll 28 people, but its current status is unclear. You can join if you are 18 or older, don't have claustrophobia, and can follow study instructions.
- Study design
- This is an interventional study planning to enroll 28 participants. It is a first-in-human evaluation of the imaging agent.
- What's involved
- You would undergo PET/CT scans at different times. The study also involves evaluating radiotracer pharmacodynamics and correlating imaging with tissue measurements.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 2 years, suggesting follow-up for at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07473102
PET Imaging of MMP Activation in AAA: Clinical Component
Recruiting
EARLY_PHASE1Ages 18+InterventionalDiagnosticWashington University School of MedicineInvestigator-initiated
~28 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Cu-64-RYM2PET imaging using Cu-64
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Verification Cu-64RYM2-2 signal in AAA segments. This will be performed by measuring Standard Uptake Values obtained from analysis of the Cu-64RYM2 images, in AAA patients.
Measured over 2 years
Conditions
Where it's being run
1 sites across 1 statesMissouri1
Study leadership
- Robert Gropler, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions.
Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
Capable of lying still and supine within the PET/CT scanner for \~1 hour and follow instructions for breathing protocol during the CT portion.
No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year.
No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
BMI ≤ 40
Men or women 40-80 years of age
Willing and able to provide informed consent
Medically managed hypertension and hyperlipidemia
No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol
Patients with AAA indicated for surgical repair (5.0 \[female\] - 5.5cm \[male\]), incidentally identified large(r) AAAs (\>5.5 or 6.0 cm), and rapidly expanding AAAs (\> 0.5 cm in 6 months or \> 1 cm in 12 months) per Guidelines of the Society for Vascular Surgery.
Exclusion
Inability to receive and sign informed consent;
Pregnant (confirmed by urine pregnancy test) and/or breastfeeding
Patient with chronic renal disease whose glomerular filtration rate (GFR) is less than 30 mL/min/1.73 m2
Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.
Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history).
Currently using recreational drugs.
Body weight of \>300 lbs. (weight limit of the PET table).
Currently enrolled in another study using an investigational drug or underwent a study the last year involving investigational use of radiotracers or CT would confound results or with a radiation exposure when combined with this study would be deemed as excessive by the Sponsor-Investigator.
Inability to receive and sign informed consent.
Currently enrolled in another study using an investigational drug
Pregnant (confirmed by urine pregnancy test) and/or breastfeeding
Patient with chronic renal disease whose GFR is less than 30 mL/min/1.73 m2
Documented allergy to iodinated contrast and/or shellfish
Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.
Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET/CT.
Other conditions such as symptomatic/recently treated coronary disease, cancer requiring oncologic management, or autoimmune/inflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis).
Non-AAA volunteers may not carry a diagnosis of aortoiliac occlusive disease, as documented by their treating vascular surgeon, as significantly progressed atherosclerotic disease may demonstrate exaggerated, associated MMP activity.
What this trial measures
- Verification Cu-64RYM2-2 signal in AAA segments. This will be performed by measuring Standard Uptake Values obtained from analysis of the Cu-64RYM2 images, in AAA patients.2 years
Verification Cu-64RYM-2 signal is present in AAA segment of the abdominal aorta